Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 106 to 120 of 179 results for transplantation

  1. Improving consent rates:- What are the key components of an intervention to improve consent rates?

    guidance details Comes from guidance Organ donation for transplantation: improving donor identification and consent rates for deceased...

  2. Improving rates of identification and referral of potential donors:- What are the key components of an intervention to improve identification and referral rates?

    guidance details Comes from guidance Organ donation for transplantation: improving donor identification and consent rates for deceased...

  3. Percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for ventricular tachycardia (IPG295)

    Evidence-based recommendations on percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for ventricular tachycardia. This involves using heat to destroy selected areas of the heart to prevent the occurrence or conduction of abnormal electrical activity.

  4. Robot-assisted kidney transplant (IPG609)

    Evidence-based recommendations on robot-assisted kidney transplant in adults. This involves the surgeon using a robot to help with a kidney transplant.

  5. Idiopathic pulmonary fibrosis in adults (QS79)

    This quality standard covers managing idiopathic pulmonary fibrosis (gradual scarring of the lungs) in adults. It includes diagnosis by a multidisciplinary team, managing symptoms and palliative care. It describes high-quality care in priority areas for improvement.

  6. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver (IPG691)

    Evidence-based recommendations on melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver. This involves diverting the blood flow from the liver to the rest of the body while the drug is delivered directly into the liver.

  7. Reasons for refusal for consent:- Why do families refuse to give permission for organ donation?

    guidance details Comes from guidance Organ donation for transplantation: improving donor identification and consent rates for deceased...

  8. Extracorporeal albumin dialysis for acute liver failure (IPG316)

    Evidence-based recommendations on extracorporeal albumin dialysis for acute liver failure. This involves using a dialysis machine to remove both water-soluble toxins and toxins that are attached to albumin and accumulate in liver failure.

  9. Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)

    Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.

  10. Laser correction of refractive error following non-refractive ophthalmic surgery (IPG385)

    Evidence-based recommendations on laser correction of refractive error following non-refractive ophthalmic surgery. This involves changing the shape of the cornea, so that light rays are more precisely directed onto the retina.

  11. Boston Keratoprosthesis Type I for corneal blindness (MIB91)

    NICE has developed a medtech innovation briefing (MIB) on Boston Keratoprosthesis Type I for corneal blindness .

  12. Factors predicting outcomes for people with high-grade transformation of follicular lymphoma:- In people with high-grade transformation of follicular lymphoma, which biological and clinical factors predict good outcomes with immunochemotherapy alone?

    treatment with, for example, high-dose therapy and autologous stem cell transplantation. Many factors are likely to influence outcome,...

  13. Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA954)

    Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.

  14. Immunosuppressive therapy for kidney transplant in children and young people (TA482)

    Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in children and young people. The therapies are basiliximab (Simulect), immediate-release tacrolimus (Adoport, Capexion, Modigraf, Prograf, Tacni, Vivadex), mycophenolate mofetil (Cellcept and non-branded versions), rabbit anti-human thymocyte immunoglobulin (Thymoglobuline), prolonged-release tacrolimus (Advagraf, Envarsus), mycophenolate sodium (Myfortic, Ceptava), sirolimus (Rapamune), everolimus (Certican) and belatacept (Nulojix).